Molecules

MK-6240

Target TauClass Small molecule (isoquinoline)Other names florquinitau

5ongoing trials
1radiolabelled forms
1approved products
145publications (PubMed)

Structure

Structure from the cited PubChem record (unlabelled ligand, or the labelled form when PubChem only describes that one). Conformer: PubChem (3D conformer computed by PubChem). Rotate with the mouse or a finger.

Properties (PubChem)

Molecular formula
C16H11FN4
Molar mass (g/mol)
278.28
Exact mass (Da)
278.0968
XLogP
2.5
H-bond donors
1
H-bond acceptors
4
Rotatable bonds
1
Heavy atoms
21
InChIKey
KAXAUWZJVWGFDO-UHFFFAOYSA-N
PubChem record
CID 118577045 ↗
IUPAC name
6-fluoro-3-pyrrolo[2,3-c]pyridin-1-ylisoquinolin-5-amine
SMILES
C1=CC(=C(C2=CC(=NC=C21)N3C=CC4=C3C=NC=C4)N)F

Radiolabelled forms

FormUseMolar mass (labelled form)Ongoing trialsMost advanced phaseApproval
[¹⁸F]MK-6240 Syntheses and QC ↗Imaging277.295Phase 3Tauklarify US

Ongoing trials · 5Open in the radar →

Atlas trials whose studied drug or title names this vector, with this radionuclide.

TrialPhaseStatusSponsorCountries
Tau protein tracersNCT07115238 · Alzheimer's disease and cognitive disordersPhase 3RecruitingSinotau Pharmaceutical Group1
Tau protein tracers2024-517074-17-00 · Alzheimer's disease and cognitive disordersPhase 3RecruitingCliniques Universitaires Saint-Luc1
NOMEM-Tau · Tau protein tracersNCT03389100 · Diabetes and obesityPhase 2By invitationColumbia University1
HEAD · Tau protein tracersNCT05361382 · Alzheimer's disease and cognitive disordersPhase 1Active, not recruitingTharick Pascoal3
Tau protein tracersNCT05464368 · Alzheimer's disease and cognitive disordersPhase 1Active, not recruitingWashington University School of Medicine1
Other trials listing it among the interventions (comparator, associated scan) · 3
ADRC PET · Amyloid tracersNCT07758660 · Alzheimer's disease and cognitive disordersPhase 2By invitationPatrick Lao1
ADVISe · Amyloid tracersNCT04576793 · Alzheimer's disease and cognitive disordersPhase 2RecruitingColumbia University1
[18F]3F4AP (potassium channels, demyelination)NCT06999434 · Alzheimer's disease and cognitive disordersPhase 1RecruitingYale University1

PublicationsAll publications in PubMed ↗

145 publications in PubMed for the query below; the most recent:

MK-6240[tiab] OR florquinitau[tiab]

  1. Using CA1 rather than the whole hippocampus to capture tau-PET Braak stage II Eur J Nucl Med Mol Imaging, 2026
  2. A Harmonized Visual Reading Framework for Tau PET Staging in Alzheimer Disease JAMA Neurol, 2026
  3. Amygdalar Pattern Similarity to Negative and Neutral Images, Ratings of the Images, and PET-Measured Amyloid and Tau Levels in Older Adults Without Dementia Affect Sci, 2026
  4. Evaluating early vs. late static SUVR windows of [¹⁸F]MK-6240 tau PET in Alzheimer disease: a head-to-head comparison study Eur J Nucl Med Mol Imaging, 2026
  5. Decreased cerebral metabolic rate of oxygen (CMRO(2)) is associated with increased tau deposition in Alzheimer's disease Alzheimers Dement (Amst), 2026
  6. Stage-specific regional distribution of amyloid and tau deposition across the Alzheimer's disease continuum revealed by tau-to-amyloid ratio imaging Eur J Nucl Med Mol Imaging, 2026
  7. The clinical Alzheimer's disease spectrum classified in the A/T/N framework with (18)F-Flutemetamol-Centiloid, (18)F-MK-6240-CenTauR, and (18)F-FDG-AD metaROI: a multicenter memory clinic observational study Eur J Nucl Med Mol Imaging, 2026
  8. Feynman-Kac Reweighted Schrödinger Bridge Matching for Surface-based Tau PET Harmonization ArXiv, 2026

Sources: PubChem and PubMed (NCBI), ClinicalTrials.gov and CTIS registries, approvals recorded by the atlas. PubChem data as of 28 October 2026.

Cite this page

MK-6240. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 27 October 2026. https://theranosticatlas.com/molecule/mk-6240/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.